CYT-AT1

N/A

Report date: 2024/07/08 13:49:15

First In Class

Base Information

Drug NameCYT-AT1

Drug Alias NameCYT-AT1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionEphrin type-A receptor 3 inhibitors

TargetsEphrin type-A receptor 3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCyteph Inc

China Registration ClassN/A

Develop Information

Active CompaniesCyteph Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A